The combination “has a favorable safety profile, without clinically meaningful PK DDI [pharmacokinetic drug-drug interactions],” reported lead study author Eleni Efstathiou, MD, and coauthors at the Alexandra General Hospital of Athens, in Greece. “No unexpected side effects were observed and there was no evidence of clinically meaningful drug-drug interaction. …This combination can be developed safely and limiting pharmacokinetic interactions are not anticipated”

“Feedback mechanisms observed by either agent are dissipated,” Dr. Efstathiou reported. “These promising findings are indicative of more efficacious androgen signaling inhibition in men with mCRPC.”

A total of 60 study participants were treated with enzalutamide (160 mg once daily) and AA (1 g once daily) plus prednisone (5 mg daily). Of these participants, 13% had prior chemotherapy, which a post-hoc analysis found to be associated with less benefit from this combination treatment, Dr. Efstathiou noted.

“There were no drug-related deaths,” Dr. Efstathiou said. “There were no new safety concerns.”

A total of 11 patients (18%) discontinued the combination treatment within 4 months, because of disease progression. These patients were deemed to have primary resistance, as evidenced by a lack of PSA decline.

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.